Infliximab
Treatment for Crohns Disease
Typical Dosage: 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks
Effectiveness
75%
Safety Score
40%
Clinical Trials
176
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$1,150
Side Effect Mgmt:$750
Total Annual:$11,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$55,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$18,308
Cost per Remission
$29,750
Infliximab Outcomes
for Crohns Disease
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+65%
Remission Rate
+40%
Common Side Effects
Infusion reactions
+15%
Upper respiratory tract infection
+25%
Headache
+15%
Serious infections
+4%
Malignancy (lymphoma, skin cancer)
+0.5%
Sources:
Active Clinical Trials
3 active trials recruiting for Infliximab in Crohns Disease
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
NCT05906576RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Beijing, China
Started: Sep 21, 2023
Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD
NCT06064864RECRUITINGNA
100 participants
INTERVENTIONAL
Seoul, South Korea
Started: Oct 9, 2023
InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
NCT06059989RECRUITINGPHASE3
158 participants
INTERVENTIONAL
Amsterdam, Netherlands
Started: Nov 25, 2021
Completed Clinical Trials
14 completed trials for Infliximab in Crohns Disease
Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease
NCT01442025COMPLETEDPHASE4
121 participants
INTERVENTIONAL
Amiens, France +11 more
Started: Jun 1, 2012
Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
NCT00705614COMPLETED
2.66K participants
OBSERVATIONAL
Started: Jul 1, 2003
Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease
NCT04272788COMPLETED
32 participants
OBSERVATIONAL
Wenzhou, China
Started: Jan 24, 2017
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
NCT04312659COMPLETED
38 participants
OBSERVATIONAL
Guangzhou, China +4 more
Started: Jul 15, 2020
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
NCT03890445COMPLETED
63 participants
OBSERVATIONAL
Innsbruck, Austria +17 more
Started: Jun 24, 2019
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
NCT02096861COMPLETEDPHASE3
220 participants
INTERVENTIONAL
Nashville, United States
Started: Sep 19, 2014
An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)
NCT00988832COMPLETED
380 participants
OBSERVATIONAL
Started: Feb 1, 2010
Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)
NCT00818272COMPLETED
148 participants
OBSERVATIONAL
Started: Dec 1, 2002
A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab
NCT07263477COMPLETED
900 participants
OBSERVATIONAL
Wenzhou, China
Started: Jan 1, 2020
Regulatory T-cells and Crohn's Disease
NCT02060318COMPLETED
47 participants
OBSERVATIONAL
Hvidovre, Denmark
Started: Feb 11, 2014
Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
NCT01349920COMPLETED
15 participants
OBSERVATIONAL
Started: Nov 28, 2012
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
NCT00724958COMPLETED
348 participants
OBSERVATIONAL
Started: Dec 1, 2004
A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease
NCT00207675COMPLETEDPHASE3
112 participants
INTERVENTIONAL
Started: Feb 1, 2003
Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease
NCT00004941COMPLETEDPHASE3
94 participants
INTERVENTIONAL
Started: Jul 1, 1996
Showing 20 of 178 total trials